Cyclophosphamide Toxicity

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Cyclophosphamide Toxicity trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT03555851

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a ta…

United States120 participantsStarted 2018-07-13

Treatment: Cyclophosphamide, Specimen collection

All recent trials (29 shown)

Not Yet RecruitingPhase 3

NCT07193420

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantat…

Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to…

France180 participantsStarted 2025-09

Treatment: Cyclophosphamide 35mg/kg/day, Cyclophosphamide 50mg/kg/day

CompletedPhase 2

NCT06186700

Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer

This clinical trial is a randomized clinical trial that aims to assess the usefulness of adding pentoxifylline to the neoadjuvant chemotherapy treatment protoco…

Egypt100 participantsStarted 2023-12-25

Treatment: Pentoxifylline 400mg plus chemotherapy, Chemotherapy

Cyclophosphamide Toxicity

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

All recent trials (29 shown)

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantat…

Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

All recent trials (29 shown)

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantat…

Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Influence of Timing PTCy in AlloSCT

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients…

Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stag…

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Alpha-Lipoic Acid in Breast Cancer Patients

Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient

Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for…

Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT

Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early…

Neurovascular Changes Induced by Chemotherapy

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tum…

Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma

Early Cardiac Toxicity of Adjuvant CT in Elderly BC.

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or…